Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Sandra Ares"'
Autor:
María F. Mercogliano, Gloria Inurrigarro, Mara De Martino, Leandro Venturutti, Martín A. Rivas, Rosalía Cordo-Russo, Cecilia J. Proietti, Elmer A. Fernández, Isabel Frahm, Sabrina Barchuk, Daniel H. Allemand, Silvina Figurelli, Ernesto Gil Deza, Sandra Ares, Felipe G. Gercovich, Eduardo Cortese, Matías Amasino, Pablo Guzmán, Juan C. Roa, Patricia V. Elizalde, Roxana Schillaci
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Invasive micropapillary carcinoma of the breast (IMPC) is a histological tumor variant that occurs with low frequency characterized by an inside-out formation of tumor clusters with a pseudopapillary arrangement. IMPC is an aggres
Externí odkaz:
https://doaj.org/article/58b71ec24f974724a0c1d23b8fb44294
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::996f48f70c83a23c9e9ef6348b353e21
https://doi.org/10.1158/1078-0432.22465440
https://doi.org/10.1158/1078-0432.22465440
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Figure S1. Aggressive features of tumors overexpressing TNFα. A-C, H&E staining of BT-474 T2 tumors showing A, muscle and B, dermis infiltration (depicted by arrows). C, peritumor leukocyte infiltration (arrow). D, histopathological an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26f53b3189418226eec43a4d093e1263
https://doi.org/10.1158/1078-0432.22465452.v1
https://doi.org/10.1158/1078-0432.22465452.v1
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Figure S2. Determination and scoring of MUC4 and TNFα expression in breast cancer biopsies by IHC. A, tissue microarrays were used to establish a score of MUC4 by IHC analysis as described by Workman et al (17). Score 0 represents no s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293fbb587e62fa5807a4b8437fd331e1
https://doi.org/10.1158/1078-0432.22465446
https://doi.org/10.1158/1078-0432.22465446
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Table S1. Patient baseline characteristics. Supplementary Table S2. Growth rate of TNFα-producing and control BT-474 tumors treated with trastuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ced8f81b9c8c9c4f054166936f6669b
https://doi.org/10.1158/1078-0432.22465455
https://doi.org/10.1158/1078-0432.22465455
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Purpose: Although trastuzumab administration improved the outcome of HER2-positive breast cancer patients, resistance events hamper its clinical benefits. We demonstrated that TNFα stimulation in vitro induces trastuzumab resistance in HER2-positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db77cf5fab880b8436f97ef09081e7a
https://doi.org/10.1158/1078-0432.c.6526023
https://doi.org/10.1158/1078-0432.c.6526023
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Revised Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb1405499bd2e24f660b6727fc42d57
https://doi.org/10.1158/1078-0432.22465458
https://doi.org/10.1158/1078-0432.22465458
Autor:
Roxana Schillaci, Patricia V. Elizalde, Juan C. Roa, Pablo Guzmán, Felipe G. Gercovich, Sandra Ares, Ernesto Gil Deza, Daniel H. Allemand, Isabel Frahm, Gloria Inurrigarro, Cecilia J. Proietti, Martín A. Rivas, Leandro Venturutti, Mara De Martino, María F. Mercogliano
Supplementary Figure S3. MUC4 expression and outcome of patients with luminal breast cancer respect. Kaplan-Meier analysis of the probability of DFS of patients with luminal breast cancer (HER2-negative, estrogen receptor-positive), based on the expr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f002712bbbd772aeb3dfaee7ff0b94e
https://doi.org/10.1158/1078-0432.22465443.v1
https://doi.org/10.1158/1078-0432.22465443.v1
Autor:
Roxana Schillaci, Sofia Bruni, Florencia Mauro, María F Mercogliano, Agustina Roldan-Deamicis, Cecilia J Proietti, Rosalía Cordo-Russo, Gloria Inurrigarro, Agustina Dupont, Carla Adami, Daniel Lopez Della Vecchia, Sabrina Barchuck, Silvina Figurelli, Ernesto Gil Deza, Sandra Ares, Felipe G Gercovich, Patricia V Elizalde
Publikováno v:
Cancer Research. 82:P5-13
Background HER2-positive (+) and triple negative breast cancer (TNBC) have the worst survival among BC. BC patients are treated with chemotherapy (CT) and/or radiotherapy (RT), and HER2+ BC patients also receive targeted therapies, such as trastuzuma
Publikováno v:
Antioxidants, Vol 12, Iss 7, p 1363 (2023)
With the rising prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) now affects 20–25% of the global population. NAFLD, a progressive condition associated with oxidative stress, can result in cirrhosis and liver cancer in 10% and 3% of
Externí odkaz:
https://doaj.org/article/39dd44a185bc41198480b3f1ba3990e3